Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05675436 · ClinicalTrials.gov registry record
Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
A clinical trial of Sickle Cell Anemia and Sickle Beta Zero Thalassemia, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Active
- Registry status
- 6
- Enrollment target
- 1
- Study location
NCT05675436 is a study of Sickle Cell Anemia and Sickle Beta Zero Thalassemia that is active but no longer recruiting, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 6 participants, below the 100-participant average among 22 other Sickle Cell Anemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05675436, a study of Sickle Cell Anemia and Sickle Beta Zero Thalassemia, is active but no longer recruiting, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- ACTIVE NOT RECRUITING
- Registry status
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen; this in turn can injure organs including the heart, lungs, and kidneys. SCD can lead to serious illness and death. Treatments such as bone marrow transplants and gene therapies can cure SCD, but they are not widely available. Current drug treatments for SCD are not always effective. This natural history study will examine how a study drug (mitapivat) affects red blood cells in people with SCD. Objective: To learn how mitapivat affects red blood cells in people with SCD. Eligibility: People with SCD who are enrolled in the parent study, NIH protocol IRB001565-H. Design: Procedures for this study will be done during visits already scheduled for the parent study. Participants will have additional blood drawn during study visits. The additional amount will be about 3.5 teaspoons. Participants will undergo a test called near infrared spectroscopy (NIRS) up to 9 times. Probes will be placed on their skin. A blood pressure cuff will be placed on their arm. The cuff will be filled with air for up to 5 minutes and then released. Participants may be asked to breathe at a certain rate or to hold their breath during these measurements. NIRS measures oxygen levels, blood flow, and the makeup of skin and muscle. Researchers will draw additional information for this study from participants medical records.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-05-09 |
| Est. Completion | 2027-10-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05675436
The ClinicalTrials.gov registry entry for NCT05675436 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 100-participant average among 22 other Sickle Cell Anemia trials with a reported enrollment target (94% lower). The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Sickle Cell Anemia appearing as the primary indexed condition, and to 0 interventions.
NCT05675436 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05675436 about?
NCT05675436 is a clinical study titled "Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease". Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen; this in turn can injure organs including the heart, lungs, and kidneys. SCD can lead to serious illness and death. Treatments such as bone marrow transplants and...
What is the current status of trial NCT05675436?
This trial is currently active not recruiting. The enrollment target is 6 participants. The study started on 2024-05-09. Estimated completion is 2027-10-27.
What conditions does trial NCT05675436 study?
This clinical trial studies the following conditions: Sickle Cell Anemia, Sickle Beta Zero Thalassemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss.
Who is sponsoring clinical trial NCT05675436?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05675436 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
RECRUITING
-
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
RECRUITING
-
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
RECRUITING · Phase 2
-
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
RECRUITING · Phase 1
-
Blood Sampling for Research Related to Sickle Cell Disease
RECRUITING
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.